Korea S.E.
23:00:00 04/07/2024 BST
5-day change
1st Jan Change
24,300
KRW
0.00%
+2.75%
-16.21%
03-27
Ray Co., Ltd. announced that it has received KRW 25 billion in funding from KB Securities Co.,Ltd, L&C BIO Co.,LTD, Samsung Securities Co.,Ltd., Shinhan Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., Hanwha Investment & Securities Co., Ltd.
CI
03-25
Ray Co., Ltd. announced that it expects to receive KRW 25 billion in funding from KB Securities Co.,Ltd, L&C BIO Co.,LTD, Samsung Securities Co.,Ltd., Shinhan Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., Hanwha Investment & Securities Co., Ltd. and other investors
CI
L&C BIO Co., Ltd announced that it has received KRW 10 billion in funding from Global Bio Partners
On March 16, 2020, L&C BIO Co., Ltd (KOSE:A290650) closed the transaction. The company has also issued warrants in the transaction.
Ray Co., Ltd. announced that it has received KRW 25 billion in funding from KB Securities Co.,Ltd, L&C BIO Co.,LTD, Samsung Securities Co.,Ltd., Shinhan Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., Hanwha Investment & Securities Co., Ltd.
03-26
CI
Ray Co., Ltd. announced that it expects to receive KRW 25 billion in funding from KB Securities Co.,Ltd, L&C BIO Co.,LTD, Samsung Securities Co.,Ltd., Shinhan Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., Hanwha Investment & Securities Co., Ltd. and other investors
03-24
CI
Plasmapp Co., Ltd. announced that it has received KRW 4.999997 billion in funding from DREAMTECH Co., Ltd., L&C Bio Co., Ltd
12-27
CI
Plasmapp Co., Ltd. announced that it expects to receive KRW 4.999997 billion in funding from DREAMTECH Co., Ltd., L&C Bio Co., Ltd
12-20
CI
Tranche Update on L&C Bio Co., Ltd's Equity Buyback Plan announced on November 23, 2023.
12-08
CI
L&C Bio Co., Ltd's Equity Buyback announced on November 23, 2023, has closed with 143,884 shares, representing 0.63% for KRW 4,881 million.
11-29
CI
L&C Bio Co., Ltd announces an Equity Buyback for 143,884 shares.
11-23
CI
L&C BIO Co., Ltd authorizes a Buyback Plan.
11-22
CI
L&C Bio Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
15/05/23
CI
Curexo Inc. announced that it has received KRW 40.49999982 billion in funding from L&C Bio Co., Ltd
29/06/22
CI
L&C Bio Co., Ltd announced that it has received KRW 60 billion in funding
28/06/22
CI
L&C Bio Co., Ltd announced that it expects to receive KRW 60 billion in funding
27/06/22
CI
Curexo Inc. announced that it expects to receive KRW 40.49999982 billion in funding from L&C Bio Co., Ltd
22/05/22
CI
NanoFocusRay Co., Ltd. announced that it expects to receive KRW 3.13 billion in funding from L&C Bio Co., Ltd
15/02/22
CI
Lululab Inc. announced that it has received funding from L&C Bio Co., Ltd, Netmarble Corporation, CTK Investment Co., Ltd., Global Medical Research Center and other investors
09/11/20
CI
Tranche Update on L&C BIO Co., LTD's Equity Buyback Plan announced on June 15, 2020.
25/06/20
CI
L&C BIO Co., LTD's Equity Buyback announced on June 15, 2020, has closed with 91,996 shares, representing 1.25% for KRW 9,967.5 million.
23/06/20
CI
L&C BIO Co., LTD announces an Equity Buyback for 91,996 shares.
15/06/20
CI
L&C BIO Co., Ltd authorizes a Buyback Plan.
14/06/20
CI
L&C BIO Co., Ltd announced that it has received KRW 10 billion in funding from Global Bio Partners
15/03/20
CI
L&C BIO Co., Ltd announced that it expects to receive KRW 10 billion in funding from Global Bio Partners
05/03/20
CI
Gene Medicine Co., Ltd. announced that it has received KRW 476.475 million in funding from L & C BIO Co.,Ltd.
16/05/19
CI
Gene Medicine Co., Ltd. announced that it expects to receive KRW 476.475 million in funding from L & C BIO Co.,Ltd.
14/05/19
CI
L & C BIO Co.,Ltd.(KOSE:A290650) added to S&P Global BMI Index
18/03/19
CI
L & C BIO Co.,Ltd. has completed an IPO in the amount of KRW 24 billion.
31/10/18
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
L&C BIO Co., Ltd is a Korea-based Company mainly engaged in the regenerative medicine business. The Company mainly manufactures and sells human tissue transplant materials used for tissue repair and filler. The Company also produces and sells human tissue-based medical devices and Cosmeceuticals. Its products are used in vascular surgeries, plastic surgeries, general surgeries and others.
More about the company
1st Jan change
Capi.
-16.21% 400M +12.62% 126B -1.99% 11.73B -23.60% 6.62B +53.19% 6.51B -30.75% 3.98B +8.52% 3.44B -19.96% 2.44B -17.14% 1.88B -21.05% 1.69B
Medical Devices & Implants
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
L&C BIO CO.,LTD 
